Exact Sciences CEO Says Company Has “Attractive Long-Term Opportunity.”

Barron’s (5/2, Bary, 948K) reports that according to Exact Sciences CEO Kevin Conroy, there continues to be “big growth from the company’s colon-cancer test,” Cologuard. According to Barron’s, Exact Sciences “has successfully secured reimbursement from Medicare and most commercial insurers for the self-administered test.” Conroy says that Cologuard “could ultimately deliver revenue of $5 to $6 billion annually, more than 10 times projected 2018 sales, as physicians and U.S. consumers embrace it.” He said, “We have an attractive long-term opportunity given the size of the market and our position in it,” adding, “We’re still in the early innings.”